A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)

Martin Forster, Allan Hackshaw, Tommaso De Pas, Manuel Cobo, Pilar Garrido, Yvonne Summers, Anne-Marie C. Dingemans, Michael Flynn, David Schnell, Ute von Wangenheim, Arsene-Bienvenu Loembe, Rolf Kaiser, Siow Ming Lee

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)27-33
Number of pages7
JournalLung Cancer
Volume120
DOIs
Publication statusPublished - 1 Jun 2018

Keywords

  • Nintedanib
  • Non-small cell lung cancer
  • Squamous
  • TRIPLE ANGIOKINASE INHIBITOR
  • CLINICAL-PRACTICE GUIDELINES
  • LABEL DOSE-ESCALATION
  • BIBF 1120
  • CONTROLLED-TRIAL
  • CARBOPLATIN
  • PACLITAXEL
  • BEVACIZUMAB
  • PHARMACOKINETICS
  • ANGIOGENESIS

Cite this